Cell therapy company raises £68m to go it alone down R&D path
This article was originally published in Scrip
Executive Summary
UK cell therapy company ReNeuron has raised £68.4m to advance two of its pipeline programs to regulatory filing stages.
You may also be interested in...
ReNeuron Stroke Stem Cell Therapy Advances
Encouraging early data from a Phase II trial of ReNeuron’s stem cell therapy CTX are adding to the evidence that it can improve patients with stroke disability, setting the stage for a pivotal trial next year.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.